These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 12643475)

  • 21. Current immunotherapeutic strategies in prostate cancer.
    Grosso JF; Drake CG
    Surg Oncol Clin N Am; 2007 Oct; 16(4):861-71, x. PubMed ID: 18022549
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gene therapy for prostate cancer.
    Gdor Y; Timme TL; Miles BJ; Kadmon D; Thompson TC
    Expert Rev Anticancer Ther; 2002 Jun; 2(3):309-21. PubMed ID: 12113054
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emerging role of immunotherapy in the management of prostate cancer.
    Slovin SF
    Oncology (Williston Park); 2007 Mar; 21(3):326-33; discussion 334, 338, 346-8. PubMed ID: 17447437
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evolving treatment paradigms for locally advanced and metastatic prostate cancer.
    Dorff TB; Quek ML; Daneshmand S; Pinski J
    Expert Rev Anticancer Ther; 2006 Nov; 6(11):1639-51. PubMed ID: 17134367
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical development of immunotherapy for prostate cancer.
    Noguchi M; Koga N; Igawa T; Itoh K
    Int J Urol; 2017 Sep; 24(9):675-680. PubMed ID: 28636142
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospects of immunotherapy for the treatment of prostate carcinoma--a review.
    Hillman GG; Triest JA; Cher ML; Kocheril SV; Talati BR
    Cancer Detect Prev; 1999; 23(4):333-42. PubMed ID: 10403905
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adjunctive therapy for men with high risk localized and locally advanced prostate cancer: targeting disseminated tumor cells.
    Sokoloff MH; Rinker-Schaeffer CW; Chung LW; Brendler CB
    J Urol; 2004 Dec; 172(6 Pt 2):2539-44. PubMed ID: 15538203
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer.
    Sims RB
    Vaccine; 2012 Jun; 30(29):4394-7. PubMed ID: 22122856
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapy for metastatic prostate cancer: where are we at with sipuleucel-T?
    Lü C; Williams AK; Chalasani V; Martínez CH; Chin J
    Expert Opin Biol Ther; 2011 Jan; 11(1):99-108. PubMed ID: 21080858
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model.
    Ko SC; Gotoh A; Thalmann GN; Zhau HE; Johnston DA; Zhang WW; Kao C; Chung LW
    Hum Gene Ther; 1996 Sep; 7(14):1683-91. PubMed ID: 8886839
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunotherapy for metastatic prostate cancer.
    Drake CG
    Urol Oncol; 2008; 26(4):438-44. PubMed ID: 18593624
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advances in the treatment of metastatic prostate cancer.
    Chowdhury S; Kirby R
    Practitioner; 2013 Apr; 257(1760):15-8, 2. PubMed ID: 23724747
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New treatments for metastic prostate cancer.
    Med Lett Drugs Ther; 2010 Sep; 52(1346):69-70. PubMed ID: 20814400
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.
    Drugs R D; 2006; 7(3):197-201. PubMed ID: 16752945
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapy in the treatment of advanced prostate cancer.
    Djavan B; Nelson K; Kazzazi A; Bruhn A; Sadri H; Gomez-Pinillos A; Ferrari AC
    Can J Urol; 2011 Oct; 18(5):5865-74. PubMed ID: 22018147
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comprehensive review of immunotherapies in prostate cancer.
    Maia MC; Hansen AR
    Crit Rev Oncol Hematol; 2017 May; 113():292-303. PubMed ID: 28427519
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Strategies for the development of PSA-based vaccines for the treatment of advanced prostate cancer.
    Arlen PM; Gulley JL; Tsang KY; Schlom J
    Expert Rev Vaccines; 2003 Aug; 2(4):483-93. PubMed ID: 14711334
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunotherapy for prostate cancer: what's the future?
    Arlen PM; Dahut WL; Gulley JL
    Hematol Oncol Clin North Am; 2006 Aug; 20(4):965-83, xi. PubMed ID: 16861126
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent developments in prostate cancer biomarker research: therapeutic implications.
    Detchokul S; Frauman AG
    Br J Clin Pharmacol; 2011 Feb; 71(2):157-74. PubMed ID: 21219396
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel therapeutic approaches to advanced prostate cancer.
    Armstrong AJ; Carducci MA
    Clin Adv Hematol Oncol; 2005 Apr; 3(4):271-82. PubMed ID: 16167000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.